A new report released today by the Department of Health and Human Services outlines the Biden Administration’s plans to address high drug prices. The report recommends the pursuit of legislation that would enable price negotiation in Medicare Parts B and D, with those negotiated prices also available to the federal marketplace, commercial plans and employers who want to participate; Medicare Part D reform, including a cap on beneficiary out-of-pocket spending; and legislation that would slow price increases over time on existing drugs and speed entry of biosimilars and generics to the marketplace while increasing their prescribing by clinicians.   
  
The report also suggests a series of executive tools to be undertaken by HHS, including the testing of several models that would use value-based payments in Medicare Part B or provide additional cost-sharing support for Medicare Part D Low-income Subsidy Beneficiaries for using biosimilars or generics, as well as efforts to curb the use of anti-competitive tactics like pay-for-delay and evergreening. A separate test of cost-of-care models would look at whether such efforts can produce changes in drug utilization, reduce total spending and improve patient outcomes. 
  
The report restates the Administration’s continued support of the 340B Drug Pricing Program. 
 

Related News Articles

Headline
The AHA submitted a statement July 11 for a Senate Special Committee on Aging hearing on health care transparency and lowering health care costs. The AHA…
Headline
The Department of Health and Human Services June 26 announced beneficiary coinsurance reductions for 64 prescription drugs available through Medicare Part B.…
Headline
The AHA May 22 released a new infographic and blog highlighting how increasing drug prices and shortages are jeopardizing patient access to hospital care and…
Blog
The inability of many patients to obtain needed drug therapies due to either high prices or shortages has negatively affected patient outcomes.1 Nearly 30% of…
Headline
The Centers for Medicare & Medicaid Services May 3 announced the opening of the comment period for the Inflation Reduction Act’s Medicare Drug Price…
Headline
White House Domestic Policy Council Director Neera Tanden spoke to Annual Meeting attendees about the environment hospitals and health systems are facing and…